Humira Drug Global Market Report 2024

The humira drug market size has grown strongly in recent years. It will grow from $9.19 billion in 2023 to $9.86 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth observed in the historical period can be attributed to factors such as the introduction of biologics, advancements in biotechnology, increasing patient demand for effective treatments, and the adoption and prescribing patterns of physicians.

The humira drug market size is expected to see strong growth in the next few years. It will grow to $13.05 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The anticipated growth in the forecast period can be attributed to the entry of biosimilars into the market, changes in healthcare policies, a focus on cost-effectiveness, increased investments in research and development, and the emphasis on precision medicine and personalized treatments. Major trends expected in the forecast period include the generation of real-world evidence, expanded use of these medications in pediatric populations, a shift towards self-administered medications, the adoption of value-based pricing models, and the development of targeted therapies.

The humira drug market is anticipated to experience growth due to a rise in the incidence rate of autoimmune diseases. Autoimmune diseases involve the immune system attacking and damaging healthy tissues and cells in the body. Humira, a drug utilized for treating pain and inflammation caused by various autoimmune diseases, is expected to see increased demand in response to the growing incidence of autoimmune diseases. As of July 2021, statistics from Cleveland Clinics, a US-based non-profit academic medical center, reveal that 1 in 15 people in the U.S. suffer from an autoimmune disease. Notably, one million individuals in the U.S. are affected by lupus, while 1.4 million have Crohn’s disease or ulcerative colitis. This surge in autoimmune diseases is poised to propel the HUMIRA drug market.

The humira drug market is also witnessing significant growth due to broad regulatory approvals granted across various countries and regions. Regulatory endorsements by governments worldwide enhance the accessibility of the humira drug globally. For instance, the U.S. Food and Drug Administration (FDA) approved an efficacy supplement for HUMIRA, extending its indication for treating pediatric patients aged 5 and above with moderately to severely active ulcerative colitis in February 2021. Additionally, in April 2023, the European Commission granted marketing authorization for a citrate-free high concentration formulation (HCF) of the biosimilar Hyrimoz (adalimumab) in the European Union. The expansive regulatory approvals for Humira contribute significantly to the ongoing growth of the humira drug market.

Product innovation stands out as a key trend in the humira drug market, with major companies developing new biologics and biosimilars to maintain their market positions. In April 2023, Sandoz, a Switzerland-based pharmaceutical company, introduced the Biosimilar Hyrimoz (adalimumab), featuring a citrate-free high-concentration formulation (HCF) approved by the European Commission. This innovative formulation provides a 50% reduction in injection volume and offers an improved experience for patients with various diseases, including rheumatic diseases and Crohn's disease.

Major companies in the humira drug market are actively focusing on the development of biosimilars for humira drugs. This strategic approach aims to enhance the cost-effectiveness of humira drugs by producing specialty biosimilars tailored for these medications. In October 2023, Boehringer Ingelheim, a Germany-based pharmaceutical company, launched a biosimilar of Humira, approved by the US Food and Drug Administration as interchangeable with the original product, offering a more cost-effective alternative.

In August 2023, CVS Health Corporation, a US-based pharmacy company, entered into a partnership with Sandoz Group AG, a Switzerland-based pharmaceuticals company. This collaboration aims to create a nearly identical drug at a significantly lower cost than the popular arthritis treatment Humira. The partnership establishes Cordavis, a new subsidiary of Novartis, with a primary focus on ensuring the supply of novel biosimilar medications. This strategic move positions CVS Health to compete effectively in the biosimilars market, projected to reach $100 billion in sales over the next six years.

Major companies operating in the humira drug market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Fresenius Kabi AG, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sandoz International GmbH, Hikma Pharmaceuticals PLC, Celltrion Healthcare Co. Ltd., Cadila Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Mochida Pharmaceutical Co. Ltd., Innovent Biologics Inc., Biocad Biopharmaceutical Company, Shanghai Henlius Biotech Inc., Glenmark Pharmaceuticals Ltd., Samsung Bioepis Co Ltd., Hetero Healthcare Ltd., Coherus BioSciences Inc., CinnaGen Co., Alvotech Holdings S.A, Reliance Life Sciences Private Limited, Momenta Pharmaceuticals Inc., Bio-Thera Solutions Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., BioXpress Therapeutics SA, Alteogen Inc., Prestige BioPharma Pte. Ltd.

North America was the largest region in the humira drug market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the humira drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the humira drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary forms of Humira drugs are Humira syringes and Humira pens. Humira syringes are a form of treatment specifically used for progressive rheumatoid arthritis. The diverse applications of Humira include treating conditions such as ankylosing spondylitis, rheumatoid arthritis, Crohn's disease, and others. These drugs are employed by various end-users, including hospitals, specialty clinics, and other healthcare facilities.

The humira drugs market research report is one of a series of new reports that provides humira drugs market statistics, including humira drugs industry global market size, regional shares, competitors with a humira drugs market share, detailed humira drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the humira drugs industry. This humira drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The humira drug market consists of sales of single-dose pen, a single-dose prefilled syringe, and a single-dose vial of liquid solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.